Neurotoxicity and Other Pharmacological Activities of the Snake Venom Phospholipase A2 OS2:  The N-Terminal Region Is More Important Than Enzymatic Activity

• Published in: Biochemistry (Easton) Vol. 45; no. 18; pp. 5800 - 5816
• Main Authors: Rouault, Morgane, Rash, Lachlan D, Escoubas, Pierre, Boilard, Eric, Bollinger, James, Lomonte, Bruno, Maurin, Thomas, Guillaume, Carole, Canaan, Stéphane, Deregnaucourt, Christiane, Schrével, Joseph, Doglio, Alain, Gutiérrez, José María, Lazdunski, Michel, Gelb, Michael H, Lambeau, Gérard
• Format: Journal Article
• Language: English
• Published: United States American Chemical Society 09-05-2006
• Subjects: Amino Acid Sequence; Animals; Biochemistry, Molecular Biology; Cellular Biology; Chickens; Drosophila; Electrophoresis, Polyacrylamide Gel; Escherichia coli - drug effects; HIV - drug effects; HIV - physiology; Life Sciences; Male; Models, Molecular; Molecular Sequence Data; Phospholipases A - chemistry; Phospholipases A - metabolism; Phospholipases A - pharmacology; Phospholipases A - toxicity; Phospholipases A2; Plasmodium falciparum - drug effects; Protein Conformation; Sequence Homology, Amino Acid; Snake Venoms - enzymology; Virus Replication - drug effects
• ISSN: 0006-2960; 1520-4995
• DOI: 10.1021/bi060217r

Several snake venom secreted phospholipases A2 (sPLA2s) including OS2 exert a variety of pharmacological effects ranging from central neurotoxicity to anti-HIV activity by mechanisms that are not yet fully understood. To conclusively address the role of enzymatic activity and map the key structural elements of OS2 responsible for its pharmacological properties, we have prepared single point OS2 mutants at the catalytic site and large chimeras between OS2 and OS1, a homologous but nontoxic sPLA2. Most importantly, we found that the enzymatic activity of the active site mutant H48Q is 500-fold lower than that of the wild-type protein, while central neurotoxicity is only 16-fold lower, providing convincing evidence that catalytic activity is at most a minor factor that determines central neurotoxicity. The chimera approach has identified the N-terminal region (residues 1−22) of OS2, but not the central one (residues 58−89), as crucial for both enzymatic activity and pharmacological effects. The C-terminal region of OS2 (residues 102−119) was found to be critical for enzymatic activity, but not for central neurotoxicity and anti-HIV activity, allowing us to further dissociate enzymatic activity and pharmacological effects. Finally, direct binding studies with the C-terminal chimera, which poorly binds to phospholipids while it is still neurotoxic, led to the identification of a subset of brain N-type receptors which may be directly involved in central neurotoxicity.